-+ 0.00%
-+ 0.00%
-+ 0.00%

Alterity Therapeutics Presents Data On Orthostatic Hypotension From Its ATH434-201 Phase 2 Clinical Study In Multiple System Atrophy

Benzinga·11/10/2025 12:27:14
Listen to the news

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that analyses on the baseline characteristics related to orthostatic hypotension (OH) from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) were featured in an oral presentation at the American Autonomic Society (AAS) 36th International Symposium on the Autonomic Nervous System that took place in Clearwater Beach, Florida, USA.